Japanese deal for Gentronix
GENTRONIX, the Manchester-based toxicity screening company, has agreed a deal with Japanese pharma group Kowa.
Under the terms of the deal Gentronix will conduct genotoxicity screening of compounds for Kowa for use in selected therapeutic products in its development pipeline.
About 100 pharmaceutical and chemical companies in 17 countries have used Gentronix’s technology as part of their genotoxicity profiling strategy.
Chief executive John Nicholson said: “Gentronix is delighted to be working with Kowa in the Japanese market.
“We believe that the Gentronix GreenScreen assay with its outstanding specificity, high sensitivity and low compound requirement, is an ideal assay, as an early screen, to assist medicinal chemists make high quality compound decisions, improve attrition rates and avoid the late stage failure of drug candidates.”
Gentronix is a university spin-out company based at the University of Manchester Innovation Centre (UMIC).
